Medical Condition News

RSS

FDA approves Halaven therapy for metastatic late-stage breast cancer

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.

16 Nov 2010

Food, drugs of abuse engage same brain systems, show studies

New animal research helps explain why some eat without hunger or to excess. The studies explore the biological effects of poor eating habits, showing that high-fat diets cause lasting brain changes that may impair healthy eating. Additional studies show that food and drugs of abuse engage many of the same brain systems. The findings were presented at Neuroscience 2010, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health.

16 Nov 2010

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.

16 Nov 2010

RBC boosting drugs may undermine breast cancer treatment with Herceptin

Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of Texas MD Anderson Cancer Center report in the Nov. 16 edition of Cancer Cell.

16 Nov 2010

Teenage binge drinking could cause mental health problems in adulthood: Study

Binge-drinking teenagers may be putting themselves at higher risk in adulthood for mood disorders such as anxiety and depression, Loyola University Health System researchers report.

16 Nov 2010

Diffusion Pharmaceuticals presents positive results of TSC study for PAD at American Heart Association

Diffusion Pharmaceuticals LLC today announced positive results of its Phase I/II proof-of-concept study of Trans Sodium Crocetinate (TSC) in patients suffering from walking impairment due to peripheral artery disease (PAD).

16 Nov 2010

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

Beth Israel Deaconess Medical Center (BIDMC) will join the Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet), a clinical research network sponsored by the National Heart Lung and Blood Institute (NHLBI) to conduct randomized clinical trials to evaluate new and existing medications for the treatment of idiopathic pulmonary fibrosis (IPF). The network is made up of healthcare institutions from around the United States.

16 Nov 2010

cTnT blood biomarker may predict risk of cardiovascular problems: Study

Certain measures of the blood biomarker cardiac troponin T (cTnT), a cardiac-specific protein, using a highly sensitive test, are associated with the development of heart failure or cardiovascular death in older adults, according to a study that will appear in the December 8 issue of JAMA. The study is being released early online because it will be presented at the American Heart Association's annual meeting.

16 Nov 2010

Oramed presents ORMD-0801 Phase IIb results for Type II diabetes at Annual Meeting in Bethesda

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, double-blind study conducted in 29 patients with Type II diabetes assessed the safety of ORMD-0801 in patients with Type II diabetes.

16 Nov 2010

Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced a total of 11 ZEVALIN related data presentations (five oral, six posters) at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

15 Nov 2010

Researchers find additional work of oxytocin hormone

New human research suggests the chemical oxytocin dubbed the "cuddle hormone" because of its importance in bonding between romantic partners and mothers and children also influences feelings of well-being and sensitivity to advertising.

15 Nov 2010

Sangart's MP4CO receives orphan drug designation for acute pain in sickle cell disease

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced that its investigational biopharmaceutical product, MP4CO, has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA) for use in treating acute painful sickling crises in patients with sickle cell disease.

15 Nov 2010

New investigational drug is well tolerated in children with nmCF

PTC Therapeutics, Inc. today announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic fibrosis (nmCF) in the American Journal of Respiratory and Critical Care Medicine.

15 Nov 2010

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

15 Nov 2010

High-dose prescription omega-3 does not reduce recurrence of atrial fibrillation

Although some data have suggested that omega-3 fatty acid supplements, such as from fish oil, may improve treatment of atrial fibrillation, a randomized trial with more than 600 patients finds that treatment with high-dose prescription omega-3 did not reduce the recurrence of atrial fibrillation over six months, according to a study that will appear in the December 1 issue of JAMA. The study is being released early online because it will be presented at the American Heart Association's annual meeting.

15 Nov 2010

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.

15 Nov 2010

PGxHealth presents results from studies using FAMILION genetic testing at 2010 AHA

Clinical Data, Inc., today announced that results of studies using its FAMILION® genetic testing were presented at the 2010 American Heart Association (AHA) meeting. PGxHealth, a division of Clinical Data, together with its collaborators, presented results from the largest, most comprehensive studies of genetic variation associated with certain cardiac conditions that were revealed using FAMILION testing.

15 Nov 2010

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

GTx, Inc. announced the presentation of preclinical studies evaluating GTx-758, a selective estrogen receptor alpha agonist being developed for first line treatment of advanced prostate cancer, and GTx-230, a novel microtubule polymerization inhibitor.

15 Nov 2010

Graphic images of negative consequences of smoking have greatest impact on smokers

Marketing researchers at the University of Arkansas, Villanova University and Marquette University surveyed more than 500 U.S. and Canadian smokers and found that the highly graphic images of the negative consequences of smoking have the greatest impact on smokers' intentions to quit. The most graphic images, such as those showing severe mouth diseases, including disfigured, blackened and cancerous tissue, evoked fear about the consequences of smoking and thus influenced consumer intentions to quit.

15 Nov 2010

50% of nut allergic patients not able to recognize nut types

Only half of people with peanut or tree nut allergies know what the nut they are allergic to looks like, according to a study presented at the American College of Allergy, Asthma and Immunology annual meeting in Phoenix Nov. 11-16. Researchers assembled a nut display that held peanuts and nine tree nuts in 19 different forms. A worksheet, which listed the items, was completed by 1,105 participants 6 years or older. Responses were analyzed based on demographics, presence or absence of food allergies, and occupational history.

15 Nov 2010

Medical Condition News

FDA approves Halaven therapy for metastatic late-stage breast cancer

Food, drugs of abuse engage same brain systems, show studies

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

RBC boosting drugs may undermine breast cancer treatment with Herceptin

Teenage binge drinking could cause mental health problems in adulthood: Study

Diffusion Pharmaceuticals presents positive results of TSC study for PAD at American Heart Association

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

cTnT blood biomarker may predict risk of cardiovascular problems: Study

Oramed presents ORMD-0801 Phase IIb results for Type II diabetes at Annual Meeting in Bethesda

Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

Researchers find additional work of oxytocin hormone

Sangart's MP4CO receives orphan drug designation for acute pain in sickle cell disease

New investigational drug is well tolerated in children with nmCF

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

High-dose prescription omega-3 does not reduce recurrence of atrial fibrillation

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

PGxHealth presents results from studies using FAMILION genetic testing at 2010 AHA

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

Graphic images of negative consequences of smoking have greatest impact on smokers

50% of nut allergic patients not able to recognize nut types

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News